Verena I. Leussink

1.0k total citations
20 papers, 591 citations indexed

About

Verena I. Leussink is a scholar working on Pathology and Forensic Medicine, Immunology and Neurology. According to data from OpenAlex, Verena I. Leussink has authored 20 papers receiving a total of 591 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pathology and Forensic Medicine, 8 papers in Immunology and 6 papers in Neurology. Recurrent topics in Verena I. Leussink's work include Multiple Sclerosis Research Studies (13 papers), Polyomavirus and related diseases (6 papers) and Peripheral Neuropathies and Disorders (4 papers). Verena I. Leussink is often cited by papers focused on Multiple Sclerosis Research Studies (13 papers), Polyomavirus and related diseases (6 papers) and Peripheral Neuropathies and Disorders (4 papers). Verena I. Leussink collaborates with scholars based in Germany, United States and Austria. Verena I. Leussink's co-authors include Hans‐Peter Hartung, Bernd C. Kieseier, Stefan Jung, Thomas Dehmel, Ralf Gold, Klaus V. Toyka, Ursula Merschdorf, Olaf Stüve, Orhan Aktaş and Norbert Goebels and has published in prestigious journals such as The Journal of Immunology, Neurology and Acta Neuropathologica.

In The Last Decade

Verena I. Leussink

20 papers receiving 575 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Verena I. Leussink Germany 14 331 229 162 106 77 20 591
G. Niederwieser Austria 10 165 0.5× 194 0.8× 92 0.6× 73 0.7× 111 1.4× 15 546
Jitesh Rana United States 4 247 0.7× 82 0.4× 123 0.8× 82 0.8× 55 0.7× 10 382
Nuwan Kurukulasuriya United States 13 369 1.1× 91 0.4× 79 0.5× 161 1.5× 81 1.1× 38 552
Y.K Semra United Kingdom 14 258 0.8× 121 0.5× 214 1.3× 74 0.7× 255 3.3× 19 606
Casey MM Pfluger Australia 9 106 0.3× 201 0.9× 133 0.8× 69 0.7× 55 0.7× 11 428
Ariele L. Greenfield United States 7 182 0.5× 107 0.5× 168 1.0× 67 0.6× 60 0.8× 9 399
Kyoichi Nomura Japan 12 406 1.2× 449 2.0× 117 0.7× 48 0.5× 86 1.1× 34 700
Laura Negrotto Argentina 8 459 1.4× 188 0.8× 88 0.5× 111 1.0× 126 1.6× 17 644
R. Gold Germany 12 103 0.3× 180 0.8× 147 0.9× 59 0.6× 70 0.9× 20 448
Linlin Wan China 10 131 0.4× 81 0.4× 359 2.2× 61 0.6× 144 1.9× 36 699

Countries citing papers authored by Verena I. Leussink

Since Specialization
Citations

This map shows the geographic impact of Verena I. Leussink's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Verena I. Leussink with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Verena I. Leussink more than expected).

Fields of papers citing papers by Verena I. Leussink

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Verena I. Leussink. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Verena I. Leussink. The network helps show where Verena I. Leussink may publish in the future.

Co-authorship network of co-authors of Verena I. Leussink

This figure shows the co-authorship network connecting the top 25 collaborators of Verena I. Leussink. A scholar is included among the top collaborators of Verena I. Leussink based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Verena I. Leussink. Verena I. Leussink is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Graf, Jonas, Verena I. Leussink, Klaudia Lepka, et al.. (2021). Relapse-independent multiple sclerosis progression under natalizumab. Brain Communications. 3(4). fcab229–fcab229. 26 indexed citations
2.
Leussink, Verena I.. (2019). Aspekte der Ernährung zur Prävention und Therapie chronisch neurologischer Erkrankungen. Der Nervenarzt. 90(8). 843–857. 2 indexed citations
3.
Leussink, Verena I., J. Reifenberger, & Hans‐Peter Hartung. (2018). Case of alopecia universalis associated with alemtuzumab treatment in MS. Neurology Neuroimmunology & Neuroinflammation. 5(3). 8 indexed citations
4.
Leussink, Verena I., Xavier Montalbán, & Hans‐Peter Hartung. (2018). Restoring Axonal Function with 4-Aminopyridine: Clinical Efficacy in Multiple Sclerosis and Beyond. CNS Drugs. 32(7). 637–651. 16 indexed citations
5.
Graf, Jonas, Verena I. Leussink, Thomas Dehmel, et al.. (2017). Infectious risk stratification in multiple sclerosis patients receiving immunotherapy. Annals of Clinical and Translational Neurology. 4(12). 909–914. 11 indexed citations
6.
Leussink, Verena I., Hans‐Peter Hartung, Bernd C. Kieseier, & Mark Stettner. (2016). Subcutaneous immunoglobulins in the treatment of chronic immune-mediated neuropathies. Therapeutic Advances in Neurological Disorders. 9(4). 336–343. 13 indexed citations
7.
Leussink, Verena I., et al.. (2016). Safety and efficacy of dimethyl fumarate in multiple sclerosis: a multi-center observational study. Journal of Neurology. 263(8). 1626–1632. 32 indexed citations
8.
Dehmel, Thomas, Susann Pankratz, Verena I. Leussink, et al.. (2014). Monomethylfumarate reduces in vitro migration of mononuclear cells. Neurological Sciences. 35(7). 1121–1125. 9 indexed citations
9.
Hörste, Gerd Meyer zu, Anne K. Mausberg, Hans-Joachim Partke, et al.. (2014). Thymic Epithelium Determines a Spontaneous Chronic Neuritis in Icam1tm1JcgrNOD Mice. The Journal of Immunology. 193(6). 2678–2690. 18 indexed citations
10.
Warnke, Clemens, Thomas Dehmel, Ryan Ramanujam, et al.. (2014). Initial lymphocyte count and low BMI may affect fingolimod-induced lymphopenia. Neurology. 83(23). 2153–2157. 23 indexed citations
11.
Kieseier, Bernd C., Olaf Stüve, Thomas Dehmel, et al.. (2012). Disease Amelioration With Tocilizumab in a Treatment-Resistant Patient With Neuromyelitis Optica. JAMA Neurology. 70(3). 390–390. 106 indexed citations
12.
Leussink, Verena I., Leila Husseini, Clemens Warnke, et al.. (2012). Symptomatic therapy in multiple sclerosis: the role of cannabinoids in treating spasticity. Therapeutic Advances in Neurological Disorders. 5(5). 255–266. 35 indexed citations
13.
Warnke, Clemens, Verena I. Leussink, Norbert Goebels, et al.. (2011). Cladribine as a therapeutic option in multiple sclerosis. Clinical Immunology. 142(1). 68–75. 10 indexed citations
14.
Husseini, Leila, Verena I. Leussink, Clemens Warnke, H.‐P. Hartung, & B. C. Kieseier. (2011). Cannabinoide zur symptomatischen Therapie der Multiplen Sklerose. Der Nervenarzt. 83(6). 695–704. 2 indexed citations
15.
Leussink, Verena I., et al.. (2009). Cladribine impedesin vitromigration of mononuclear cells: a possible implication for treating multiple sclerosis. European Journal of Neurology. 16(3). 409–412. 36 indexed citations
16.
Stüve, Olaf, Verena I. Leussink, Bernhard Hemmer, et al.. (2009). Long-term B-Lymphocyte Depletion With Rituximab in Patients With Relapsing-Remitting Multiple Sclerosis. Archives of Neurology. 66(2). 259–61. 37 indexed citations
17.
Kieseier, Bernd C., Heinz Wiendl, Verena I. Leussink, & Olaf Stüve. (2008). Immunomodulatory treatment strategies in multiple sclerosis. Journal of Neurology. 255(S6). 15–21. 22 indexed citations
18.
Leussink, Verena I., D. Brechtelsbauer, Martin Bendszus, et al.. (2003). Superficial siderosis of the central nervous system: pathogenetic heterogeneity and therapeutic approaches. Acta Neurologica Scandinavica. 107(1). 54–61. 36 indexed citations
19.
Leussink, Verena I., Uwe K. Zettl, Sebastian Jander, et al.. (2002). Blockade of signaling via the very late antigen (VLA-4) and its counterligand vascular cell adhesion molecule-1 (VCAM-1) causes increased T cell apoptosis in experimental autoimmune neuritis. Acta Neuropathologica. 103(2). 131–136. 43 indexed citations
20.
Leussink, Verena I., Stefan Jung, Ursula Merschdorf, Klaus V. Toyka, & Ralf Gold. (2001). High-Dose Methylprednisolone Therapy in Multiple Sclerosis Induces Apoptosis in Peripheral Blood Leukocytes. Archives of Neurology. 58(1). 91–7. 106 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by G. Niederwieser Breakdown of academic impact, for papers by Jitesh Rana Breakdown of academic impact, for papers by Nuwan Kurukulasuriya Breakdown of academic impact, for papers by Y.K Semra Breakdown of academic impact, for papers by Casey MM Pfluger Breakdown of academic impact, for papers by Ariele L. Greenfield Breakdown of academic impact, for papers by Kyoichi Nomura Breakdown of academic impact, for papers by Laura Negrotto Breakdown of academic impact, for papers by R. Gold Breakdown of academic impact, for papers by Linlin Wan
Rankless by CCL
2026